---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002831"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T12:00:22.678314+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports FY2022 net loss of $136.1M; cash runway into H1 2025; clinical updates for GM1 and FTD

## Summary
- Cash and marketable securities $189.6M at Dec 31, 2022, down from $315.8M; runway into first half of 2025.
- FY2022 net loss $136.1M ($2.50 per share) vs $185.4M ($3.48) in 2021; R&D expenses $86.1M.
- PBGM01 for GM1 gangliosidosis: interim data shows biological effect; plan to dose first patient at higher dose in H2 2023.
- upliFT-D trial for FTD-GRN: enrollment ongoing; initial safety/biomarker data from Cohort 1 expected H2 2023.

## SEC filing metadata
- accession: 0001558370-23-002831
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/0001558370-23-002831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/pasg-20230306x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002831
- JSON: https://secwatch.observer/filing/0001558370-23-002831.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002831.txt

## Key facts
- Earnings Releases
  Passage BIO, Inc. reported the fourth quarter ended December 31, 2022 results: net income Net loss was $27.1 million, EPS $0.50 per basic and diluted share.
  - Period: the fourth quarter ended December 31, 2022
  - Net income: Net loss was $27.1 million
  - EPS: $0.50 per basic and diluted share
  - Result: reported results
  source text: Net loss was $27.1 million, or a net loss of $0.50 per basic and diluted share, for the quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/0001558370-23-002831-index.htm
- Earnings Releases
  Passage BIO, Inc. reported the year ended December 31, 2022 results: net income Net loss was $136.1 million, EPS $2.50 per basic and diluted share.
  - Period: the year ended December 31, 2022
  - Net income: Net loss was $136.1 million
  - EPS: $2.50 per basic and diluted share
  - Result: reported results
  source text: $136.1 million, or a net loss of $2.50 per basic and diluted share, for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000155837023002831/0001558370-23-002831-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.